Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.48 |
| ▸ | JUN | P05412 | 4/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.48 |
| ▸ | TTK | P33981 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846917 | 0.88 | JAK2 (0.70) | JAK2BRD4EGFRFGFR2MAPK10 | |
| SCHEMBL16514362 | 0.88 | JAK2 (0.70) | JAK2BRD4EGFRFGFR2MAPK10 | |
| SCHEMBL16514799 | 0.85 | JAK2 (0.66) | JAK2BRD4EGFRFGFR2MAPK10 | |
| SCHEMBL29847922 | 0.84 | JAK2 (0.56) | JAK2BRD4EGFRFGFR2MAPK10 | |
| SCHEMBL16514760 | 0.84 | JAK2 (0.56) | JAK2BRD4EGFRFGFR2MAPK10 | |
| SCHEMBL29848096 | 0.84 | FGFR2 (0.71) | JAK2BRD4EGFRFGFR2MAPK10 | |
| SCHEMBL16515483 | 0.84 | FGFR2 (0.71) | JAK2BRD4EGFRFGFR2MAPK10 | |
| SCHEMBL16823075 | 0.81 | CDK4 (0.48) | JAK2BRD4EGFRFGFR2FGFR1 | |
| SCHEMBL16513630 | 0.77 | JAK2 (0.56) | JAK2BRD4EGFRFGFR2MAPK10 | |
| SCHEMBL29847837 | 0.77 | JAK2 (0.56) | JAK2BRD4EGFRFGFR2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | JAK2 53/4885BRD4 658/4885EGFR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.